Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

640 results about "Lipid peroxidation" patented technology

Lipid peroxidation is the oxidative degradation of lipids. It is the process in which free radicals "steal" electrons from the lipids in cell membranes, resulting in cell damage. This process proceeds by a free radical chain reaction mechanism. It most often affects polyunsaturated fatty acids, because they contain multiple double bonds in between which lie methylene bridges (-CH₂-) that possess especially reactive hydrogen atoms. As with any radical reaction, the reaction consists of three major steps: initiation, propagation, and termination. The chemical products of this oxidation are known as lipid peroxides or lipid oxidation products (LOPs).

Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens

A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC

Methods of treating chronic inflammatory diseases using carbonyl trapping agents

InactiveUS6444221B1Improved therapeutic propertyImprove propertiesBiocidePeptide/protein ingredientsEtiologyBenzoic acid
These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).
Owner:SECANT PHARMA

Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis

The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.
Owner:ZABRECKY GEORGE

Liquid nutrient composition for improving performance

Novel, advantageous oral compositions formulated to affect any one or combination of the following: reduce physical and mental fatigue, enhance activity, improve recovery from activity, promote muscle performance, increase energy substrates, contribute to improved antioxidant defenses (i.e., reduce oxidative stress or lipid peroxidation, conserve anti-oxidants in the sera), enhance mood, assist in preventing primary and secondary diseases associated with fatigue and muscle atrophy associated with inactivity, improve nervous system (i.e., neuronal) and musculoskeletal (i.e., increase skeletal muscle protein synthesis, increase satellite cells) health, and contribute to improvements in overall health. The compositions of the subject invention are preferably used as a replacement for a snack or meal in cases of hunger or fatigue for individuals across the broad spectrum of human function from elite athletes to those individuals compromised by aging and certain disease states.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene

The methods of the invention can be used to protect against lymphocyte DNA damage and free-radical associated disorders in a subject. The methods of the present invention can be used to increase the antioxidant capacity in both the aqueous and lipid compartments, decrease DNA oxidation, decrease lipid peroxidation, and increase antioxidant nutrient levels in the circulation. The protective effect of the physiologic dose of the mixed carotenoid supplement is rapid, consistent and cumulative.
Owner:TRUSTEES OF TUFTS COLLEGE TUFTS UNIV

Materials and methods for treatment of gastrointestinal disorders

The subject invention pertains to materials and methods for the prevention and treatment of gastrointestinal diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and / or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient.
Owner:THERAPEUTIC RES

Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens

A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC

Composition and method inhibiting inflammation

InactiveUS20110027348A1Preventing and treating and attenuating inflammatory diseaseIncreased omega FA contentBiocideSenses disorderDiseaseMedicine
Composition and method for preventing, treating or attenuating inflammatory diseases by way of inhibiting lipid peroxidation and subsequent elementary inflammation through ensuring the presence of the following biologically active ingredients in the PMRS of cells involved in inflammation: i) at least one killed probiotic and ii) at least one omega 3 FA and iii) vitamin E and iv) ubiquinone by introducing a composition comprising any of the missing ingredients.
Owner:FEHER JANOS

Medical devices containing rapamycin analogs

A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
Owner:ABBOTT LAB INC

Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy

The combination of amlodipine with atorvastatin metabolite shows a synergistic antioxidant effect on lipid peroxidation in human low-density lipoproteins and membrane vesicles enriched with polyunsaturated fatty acids. Inhibition of oxy-radical damage by this drug combination was observed at therapeutic levels in a manner that could not be reproduced by the combination of amlodipine with other statins or the natural antioxidant, vitamin E. The basis for this potent activity is attributed to the chemical structures of these compounds and their molecular interactions with phospholipid molecules, as determined by x-ray diffraction analyses. This combination therapy can be used to treat cardiovascular disorders, especially coronary artery disease, by increasing the resistance of low-density lipoproteins and vascular cell membranes against oxidative modification.
Owner:MASON R PRESTON

Myeloperoxidase, a risk indicator for cardiovascular disease

Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.
Owner:THE CLEVELAND CLINIC FOUND

Preparation method of fucosan sulphate oligosaccharide

A process for preparing the oligose of fucosan sulfate includes such steps as preparing the aqueous solution of fucosan sulfate, adding oxidant chosen from hydrogen peroxide, hypochlorous acid, nitrous acid, or their salts, heating, membrane ultrafilter, vacuum concentrating and freeze drying. Its advantages are high medical effect to protect liver and take care of health, and low cost.
Owner:OCEAN UNIV OF CHINA

Mussel meat protein antioxidative peptide and preparation method thereof

The invention relates to a mussel meat protein antioxidative peptide and a preparation method thereof. The invention is characterized in that the antioxidative peptide is a pentapeptide compound with an amino acid sequence of YPPAK (Tyr-Pro-Pro-Ala-Lys), and according to ESI-MS detection, a molecular ion peak of m / z [M+H]<+> 575.26 is given out. The preparation method comprises the steps consisting of slurry homogenizing, degreasing, mixing, enzymatic hydrolysis, desalination, ultrafiltration, chromatography and the like. The prepared high-activity antioxidative peptide YPPAK (Tyr-Pro-Pro-Ala-Lys) has a good removal effect on DPPH free radicals, hydroxyl free radicals and superoxide anion free radicals; meanwhile, the YPPAK (Tyr-Pro-Pro-Ala-Lys) shows a good inhibitory effect on lipid peroxidation. The YPPAK (Tyr-Pro-Pro-Ala-Lys) has the advantages of safety, no toxic and side effects, good antioxidant activity, easy digestion and absorption, etc., and can be used as a medicine, a health food or foodstuff additive and the like.
Owner:ZHEJIANG OCEAN UNIV

Composite Particles Having An Antioxidant-Based Protective System, And Topical Compositions Comprising The Same

InactiveUS20100040696A1Reduce and eliminate stressProtect the skinCosmetic preparationsBiocideSunscreen agentsDecomposition
The present invention relates to topical compositions containing a dispersion of composite particles. Each of such composite particles contains one or more core particles encapsulated or entrapped in a polymeric shell. At least some of the core particles are formed of a material capable of causing generation of reactive oxygen species (ROS). Each of the composite particles further contains: (1) a first antioxidant co-encapsulated or co-entrapped with the core particles inside the polymeric shell for quenching or scavenging ROS generated in the vicinity of the core particles, and (2) a second antioxidant coated over the polymeric shell for preventing or reducing oxidative damage to the skin, such as lipid peroxidation. The particle dispersion of the present invention therefore can be readily formulated into topical sunscreen compositions with organic sunscreen agents susceptible to oxidative decomposition or degradation to provide improved protection against skin damage caused by exposure to UV light.
Owner:ELC MANAGEMENT LLC

Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices

InactiveUS7399480B2Reduce probabilityReduces restenosis in vasculatureBiocideOrganic chemistryAnti plateletCytostatic drugs
A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to,This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
Owner:ABBOTT LAB INC

Health-care preparation capable of alleviating a hangover and protecting the liver and preparation method thereof

The invention relates to a preparation method of a heath-care preparation which has effects of alleviating hangover and protecting liver. The heath-care preparation is an oral solid preparation which takes an active indigent extract containing kudzuvine root pueraria lobata, semen hoveniae and oil orange as active ingredient. The weight proportions of the raw materials are as follows: kudzuvine root pueraria lobata: 800 to 2500, semen hoveniae: 700 to 1500, oil orange: 150 to 250, and proper amount of auxiliary materials. The preparation method takes kudzuvine root pueraria lobata and semen hoveniae which has strong effects of alleviating hangover and protecting liver as monarch drug in the prescription, takes oil orange which has effects of clearing out free radical, oxidation resistance and anti-lipid peroxidation as auxiliary materials, thus preparing the heath-care preparation which has effects of alleviating hangover and protecting liver.
Owner:昆明振华制药厂有限公司

Plant drug for treatment of liver disease

The present invention related to safe plant drug for treatment of liver disease, specifically, this invention proves a safe plant drug Schisandrin and its preparation. Schisandrin has the following pharmaceutical functions: increasing tumor suppresson genes express activity, decreasing activity of oncogenes, increasing immune function, increasing liver DNA synthesis, decreasing serum alamine aminotransferase activity, increasing glutathione level, increasing glutathione reductase activity, decreasing lipid peroxidation of liver, increasing hepatic microsomal monooxygenases activity, increasing ATP content in liver, increasing energy metabolism activity, decreasing density lipoprotein oxidation, protecting gastrointestinal function, increasing killer cell activity, increasing complement activity, decreasing induced liver cancer activity and decreasing grown of cancer cells.
Owner:ZHAO XINXIAN

Antioxidant peptide of hairtail fish protein as well as preparation method and uses of antioxidant peptide

The invention discloses an antioxidant peptide of hairtail fish protein as well as a preparation method and uses of the antioxidant peptide. In particular, hairtail fish is used as raw materials; an enzymatic hydrolysis solution is obtained through degreasing and enzymolysis of protamex and neutral protease; the enzymatic hydrolysis solution is separated and purified through ultra-filtration, purification of macroporous resins, cation exchange resin chromatography, gel column chromatography, and reversed-phase high-performance liquid chromatography so as to obtain the antioxidant peptide Asn-Trp-Asp-Met-Glu-Lys-Ile-Trp, and the ESI-MS determining molecular weight is 1121.25da. The high-activity antioxidant peptide disclosed by the invention has a good scavenging effect on DPPH free radicals, hydroxyl radicals and superoxide anion free radicals; besides, the antioxidant peptide shows a good effect of lipid peroxidation inhibition. The antioxidant peptide has the advantages of safe use, zero toxic or side effects, high oxidative activity and the like, is liable to digest and absorb, and can be used as medicines, health food or food additives, and the like.
Owner:北京姿美堂生物技术股份有限公司

Method of selecting antioxidants for use in topically applied compositions

InactiveUS20090189090A1Exhibits antioxidant activityInhibit lipid peroxidationCosmetic preparationsToilet preparationsMedicineReactive oxygen species formation
Antioxidant-containing compositions and methods for confirming antioxidant activity of a composition formulated for topical application to skin. Methods for testing a composition for ability to inhibit both ultraviolet radiation-induced lipid peroxidation on skin and ultraviolet radiation-induced reactive oxygen species formation in the stratum corneum. Compositions and methods for treating and preventing photodamage to skin.
Owner:MSD CONSUMER CARE INC

Extraction and application of exopolysaccharide metabolite of bacillus amyloliquefaciens strain

The invention discloses an extraction and an application of exopolysaccharide metabolite of a bacillus amyloliquefaciens C-1 strain. A 16s rRNA amplified fragment of the bacillus amyloliquefaciens C-1 strain is sequenced and compared with a 16s rRNA sequence of bacteria in a NCBI (national center of biotechnology information) database; a comparison result proves that the bacillus amyloliquefaciens C-1 strain belongs to B.amyloliquefaciens; and an NCBI register number of the 16s rRNA sequence of the bacillus amyloliquefaciens C-1 strain is JN974457. The bacillus amyloliquefaciens C-1 strain is collected in china center for type culture collection (CCTCC), has the effects of reducing exopolysaccharide, removing DPPH (1,1-diphenyl-2-picryl-hydrazyl) free radical, scavenging hydroxyl free radical (.OH), scavenging superoxide anion (O<2->), inhibiting lipid peroxidation and inhibiting human tumor cell proliferation, and opens up a new way and a new research field for exploring anti-tumor drugs.
Owner:XI AN JIAOTONG UNIV

Anti-aging skincare mask containing crithmum maritimum

The invention discloses an anti-aging skincare mask containing crithmum maritimum. The anti-aging skincare mask is prepared from a skin conditioner component, an auxiliary component and water, wherein the skin conditioner component is prepared from 2%-6% by mass of butanediol, 2%-5% by mass of glycerin, 0.1%-0.5% by mass of a crithmum maritimum extract, 1%-5% by mass of a pseudoalteromonas fermentation product extract, 1%-5% by mass of acetyl hexapeptide-8, 0.5%-3% by mass of a Centella asiatica extract, 0.5%-2% by mass of D-panthenol, 0.03%-0.1% by mass of sodium hyaluronate, 1%-5% by mass of Chamomile German water, 0.5%-3% by mass of corn protein amino acids, 1%-3% by mass of a lotus extract, 0.5%-2% by mass of bio-saccharide gum-1 and 0.1%-0.3% by mass of allantoin. The anti-aging skincare mask containing crithmum maritimum can inhibit lipid peroxidation and inflammatory reaction, rebuild water balance and brighten complexion and has effects of preserving moisture, resisting aging, brightening the complexion and realizing anti-allergic repair.
Owner:广州蜜妆生物科技有限公司

Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives

InactiveUS20090233876A1Reduce allergic reactionsPotent immunosuppressive effectAntibacterial agentsBiocideSolubilitySucrose
The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrhythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic antimutagenic, antineoplastic, anti-thrombotic, and vasodilatory formulations, or in any other field of application.
Owner:LIBRAGEN SA

Compositions and methods of administering paclitaxel with other drugs using medical devices

Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
Owner:ABBOTT LAB INC

Method for extracting ipomoes batatas L. anthocyanidins

The invention discloses a method for extracting ipomoes batatas L. anthocyanidins, which comprises the following steps: baking the ipomoes batatas L. by microwave, then placing the baked ipomoes batatas L. into acid electrolysis water, and repeatedly homogenizing and extracting, filtering, separating and drying the ipomoes batatas L. to prepare anthocyanidins powder. The method for extracting theanthocyanidins has the advantages of high efficiency, simple process, low cost and environmental protection; the obtained ipomoes batatas L. anthocyanidins extract has fresh and stable color; and thecontent of active ingredients such as total flavonoids, total phenols, total sugars and total monomer anthocyanidins and the like in the extract is higher. The ipomoes batatas L. anthocyanidins extract prepared by the method has stronger reducing power, capacity of eliminating free radicals and function of lipid peroxidation resistance in vitro, has quite obvious anti-oxidation effect in vivo, and can remarkably delay the ageing of the organism. The ipomoes batatas L. anthocyanidins extract can be widely used in the fields of food colorant, anti-ageing health-care food and the like.
Owner:SUZHOU UNIV

Inhibitors of hemeprotein-catalyzed lipid peroxidation

Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and / or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.
Owner:VANDERBILT UNIV

Application of withanolide compound in preparation of drug or healthcare product for treating or preventing tumors and neurodegenerative diseases

The invention discloses application of a withanolide compound in preparation of a drug or a healthcare product for treating or preventing tumors and neurodegenerative diseases. The withanolide compound has structural formulas as shown in formula I and optical isomers thereof. The research indicates that the withanolide compounds can be used for activating an Nrf2 signal channel, up regulating expression of NrF2 and downstream antioxidant and II-phase detoxifying enzymes thereof, strengthening the level of glutathione in cells, increasing reducing capacity in cells, promoting elimination of active carbon, restraining lipid peroxidation and lowering cytotoxicity caused by cancerogen arsenic and nerve cell toxicity induced by active oxygen H2O2 to show good chemical prevention effect. And therefore, the withanolide compound and nightshade extract including the withanolide compound have the potential of becoming a chemical prophylactic drug and the healthcare product, and can be used for preparing the corresponding oral preparation and injection by being used as the main ingredient, and also can be used for preventing and treating tumors and neurodegenerative diseases.
Owner:SHANDONG UNIV

Phyllanthus emblica extract and its preparation and application

The present invention relates to emblic extract and its preparation process and application. Dried emblic powder is first microwave assisted solvent extracted, and the emblic extract is then extracted with diethyl ether and ethyl acetate and macroporous resin purified to obtain purified emblic extract. The purified emblic extract is one kind of natural antioxidant with emblic polyphenol in the content over 93 % as the main effective component. The emblic extract as natural antioxidant is superior to available synthetic antioxidants, and has high DPPH free radical eliminating activity, high lipid peroxide inhibiting activity and high peroxidation resisting capacity.
Owner:SOUTH CHINA UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products